Chengdu Easton Biopharmaceuticals Co Ltd
SSE:688513
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
29.2
70.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Income Statement
Earnings Waterfall
Chengdu Easton Biopharmaceuticals Co Ltd
|
Revenue
|
1.3B
CNY
|
|
Cost of Revenue
|
-367.6m
CNY
|
|
Gross Profit
|
967.1m
CNY
|
|
Operating Expenses
|
-759.7m
CNY
|
|
Operating Income
|
207.4m
CNY
|
|
Other Expenses
|
21m
CNY
|
|
Net Income
|
228.3m
CNY
|
Income Statement
Chengdu Easton Biopharmaceuticals Co Ltd
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
0
|
1
|
1
|
3
|
3
|
4
|
4
|
3
|
4
|
4
|
4
|
4
|
3
|
0
|
|
| Revenue |
1 071
N/A
|
1 100
+3%
|
1 147
+4%
|
1 171
+2%
|
1 179
+1%
|
1 150
-2%
|
1 123
-2%
|
1 117
0%
|
1 154
+3%
|
1 231
+7%
|
1 307
+6%
|
1 350
+3%
|
1 340
-1%
|
1 335
0%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
(180)
|
(190)
|
(201)
|
(198)
|
(219)
|
(224)
|
(234)
|
(226)
|
(255)
|
(292)
|
(317)
|
(344)
|
(359)
|
(368)
|
|
| Gross Profit |
891
N/A
|
910
+2%
|
946
+4%
|
972
+3%
|
960
-1%
|
926
-4%
|
888
-4%
|
891
+0%
|
899
+1%
|
939
+4%
|
990
+5%
|
1 006
+2%
|
982
-2%
|
967
-1%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(687)
|
(690)
|
(744)
|
(750)
|
(727)
|
(703)
|
(664)
|
(687)
|
(679)
|
(719)
|
(760)
|
(793)
|
(785)
|
(760)
|
|
| Selling, General & Administrative |
(542)
|
(544)
|
(561)
|
(569)
|
(559)
|
(534)
|
(494)
|
(478)
|
(496)
|
(532)
|
(556)
|
(558)
|
(550)
|
(523)
|
|
| Research & Development |
(204)
|
(206)
|
(218)
|
(217)
|
(236)
|
(238)
|
(234)
|
(219)
|
(243)
|
(241)
|
(258)
|
(242)
|
(271)
|
(284)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(29)
|
0
|
0
|
0
|
(43)
|
0
|
0
|
0
|
(41)
|
0
|
0
|
|
| Other Operating Expenses |
59
|
60
|
35
|
65
|
68
|
69
|
65
|
53
|
59
|
53
|
54
|
48
|
35
|
48
|
|
| Operating Income |
203
N/A
|
221
+8%
|
203
-8%
|
222
+10%
|
233
+5%
|
224
-4%
|
225
+0%
|
205
-9%
|
220
+8%
|
220
0%
|
230
+5%
|
213
-8%
|
196
-8%
|
207
+6%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
51
|
44
|
46
|
38
|
38
|
35
|
36
|
37
|
33
|
37
|
31
|
39
|
38
|
35
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Total Other Income |
3
|
3
|
8
|
1
|
1
|
1
|
1
|
0
|
(0)
|
(0)
|
(0)
|
1
|
1
|
1
|
|
| Pre-Tax Income |
257
N/A
|
267
+4%
|
257
-4%
|
262
+2%
|
273
+4%
|
260
-5%
|
262
+1%
|
242
-8%
|
253
+5%
|
256
+1%
|
262
+2%
|
253
-3%
|
235
-7%
|
243
+3%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
(14)
|
(17)
|
(15)
|
(15)
|
(19)
|
(17)
|
(17)
|
(15)
|
(13)
|
(15)
|
(12)
|
(14)
|
(11)
|
(15)
|
|
| Income from Continuing Operations |
243
|
250
|
242
|
247
|
254
|
243
|
245
|
227
|
241
|
242
|
250
|
238
|
224
|
228
|
|
| Net Income (Common) |
243
N/A
|
250
+3%
|
242
-3%
|
247
+2%
|
254
+3%
|
243
-4%
|
245
+1%
|
227
-7%
|
241
+6%
|
242
+0%
|
250
+3%
|
238
-5%
|
224
-6%
|
228
+2%
|
|
| EPS (Diluted) |
2.02
N/A
|
2.08
+3%
|
2.01
-3%
|
1.4
-30%
|
2.11
+51%
|
2.03
-4%
|
2.04
+0%
|
1.29
-37%
|
1.37
+6%
|
1.35
-1%
|
1.45
+7%
|
1.36
-6%
|
1.27
-7%
|
1.3
+2%
|
|
